Einleitung Migränegehirn Jan 26, 2023 Neue Behandlung – frage nach Beweisen; ‘heilen’ dann weise die Tür. – Peter Goadsby Wer Heilung von Migräne verspricht, dem sollen wir die Tür Medienresonanz Jan 26, 2023 Bisherige Medienresonanz meiner Migräneforschung (Stand 2016 – ohne die enorme Resonanz auf das Startup) 5 Sept. 2016 Neue Therapie-App – Der Inhaltsverzeichnis Migränegehirn Jan 26, 2023 Einleitung Ich sehe was, was du nicht siehst Vorboten verschmelzen mit Auslösern Ein Tag wie querschnittsgelähmt In der Rückbildung wieder aktiv Systems Medicine Jan 26, 2023 The combinatory effects, including additive, synergistic, antagonistic, and suppression, (C) are quantified by isobologram analysis. Depending on Die 4 Variationen des Glücks Jan 25, 2023 Blankes Glück Glück durch Bewegung Glück durch fachlichen Spürsinn Glück durch ausgefallene Tätigkeit - Altamirage Rein zufälliges Glück, das völlig Inhaltsangabe Migränegehirn Jan 23, 2023 Lange galt Migräne als unsichtbare Krankheit. Nichtbetroffene unterstellten gerne auch schon mal, Migräne sei eine eingebildete Krankheit, denn es Pathway ID™ Jan 20, 2023 is designed on Model-Based Systems Engineering (MBSE) principles, providing a structured, compliant, and scalable approach to Virtual Population Jan 19, 2023 With its roots primarily in quantitative systems pharmacology (QSP), often originating from mathematical oncology, virtual populations represent DTx Discovery Jan 19, 2023 Discovery of Digital Therapeutics (DTx) follows a structured and methodical process, much like traditional drug discovery. Target Identification, Digital Twins Jan 18, 2023 Digital twins create a virtual replica of the human body’s organ system of interest, using physiological models to simulate complex interactions DTx Translation Jan 17, 2023 The translation phase transforms a lead candidate from DTx Discovery into a real-world software product by refining the DTx’s mechanism of action Support Jan 16, 2023 Focuses on adherence and managing side effects and ensuring overall patient well-being during the primary treatment DTx Development Jan 16, 2023 From Signal of Efficacy (Phase 2a) to Phase 2b (Adaptive Validation) to Phase 3 (Pivotal Trials) In Digital Therapeutics (DTx), transitioning from Priming Jan 15, 2023 Administering treatments beforehand to induce protective adaptations Reverese Translation Jan 15, 2023 Maintenance Jan 14, 2023 Continuous treatment aimed at preventing disease recurrence or maintaining remission after initial success Adjacent Jan 13, 2023 Treatment given alongside the primary therapy for a complementary effect Conccurent Jan 12, 2023 Treatment timed to align with the body’s natural rhythms, enhancing effectiveness and reducing side effects Chronotherapy Jan 11, 2023 Treatment timed to align with the body’s natural rhythms, enhancing effectiveness and reducing side effects. Example: “Smart blistering” represents Care Models Aug 15, 2022 The percentage values along the yes path (in larger font) are relative to the total (100 %) of individuals living with the condition, representing Next page